A global leader in optimized resource management providing water, waste, and energy management solutions is seeking materials, technologies, and proven processes for the production of porous, hollow tubing. Ideal parameters for produced tubing include enablement of water passage at a rate of &#x2265; 1500 L/hour/m2 at 1 bar pressure and the ability to withstand 100-700N of tensile force. Desired dimensions include a circular luminal diameter of 0.50-1.00 mm, and an external tube diameter of 1.50-1.80 mm. Resulting tubing must also exhibit flexibility and high bend...

A global leader in optimized resource management is seeking processes and materials to make porous, hollow tubing. Ideal parameters include permeability, strength, flexibility, and chemical resistance.

Seeking Materials and Processes for the Production of Porous Tubing

Nippon Kayaku, a global chemical products company, is actively seeking to advance the research and development of organic electro-optical (EO) polymer materials for modulators, switches, and optically integrated circuit (PIC) technology towards ultra high-speed and energy-saving optical communication technology. There is also interest in materials associated with photonic assemblies and protective coatings. Approaches of Interest: <ul> <li>Organic EO materials with the following characteristics are of high interest: <ul> <li>(1) High EO coefficient (r33) at O-band (1310...</li></ul></li></ul>

Nippon Kayaku is in search of organic electro-optical polymer materials, with a focus on dielectric, thermal, chemical, mechanical, and optical properties, while also emphasizing sustainability.

Seeking Organic Electro-optical Materials and/or Modulators for High-speed Communication, and Materials for Photonic Assemblies and Protective Coatings

ICL Group, a global leader in bromine- and phosphorous-based flame retardants, is seeking novel flame retardants (FRs) for a range of applications, including electronics, vehicles, textiles, and paints and coatings. Halogen- and PFAS-free FR polymer materials and replacements for antimony trioxide (ATO) as a synergist to brominated FRs are of particular interest. <h3>Approaches of Interest: </h3> <ul> <li>A broad range of FR materials are of interest, including phosphorous-containing FRs, inorganic FRs, nitrogen-containing FRs, hybrid system FRs, nanodimensional FRs, or...</li></ul>

ICL Group is seeking novel halogen- and PFAS-free flame retardant materials for a range of applications.

Seeking Next-generation Flame Retardants

A leading company in rare disease therapeutics is seeking novel treatments for rare genetic skeletal diseases and genetically defined subsets of common skeletal diseases. They are also interested in delivery techniques to target bone tissues, ideally coupled with novel therapeutics. Approaches of Interest: <ul> <li>Priority modalities of interest: non&#x2011;viral therapeutic approaches, mRNA, oligonucleotides (e.g. RNAi, siRNA, ASO, and saRNA), small molecules, protein replacement and substitution, among other novel approaches. </li> <li>Novel approaches to target delivery to...</li></ul>

A leading rare disease company is seeking novel approaches to treat rare genetic bone disease, coupled with technologies to achieve targeted delivery to bone tissues. 

Novel Therapeutic Approaches for Genetic Skeletal Diseases and Targeted Delivery to Bone

Our client, a global biotechnology company, is seeking novel approaches for site-specific targeting of therapeutics to the joint, with a specific focus on cartilage tissues. Approaches should enable therapeutics delivered systemically to be targeted to joint tissues. Enhanced delivery of oligonucleotides and biologics is of particular interest. <h3>Approaches of Interest:</h3> <ul> <li>Molecular approaches to achieve targeting to cartilage, specifically chondrocytes, or the endplate via systemic delivery is prioritised. Targeted delivery to joint connective tissue or the...</li></ul>

A leading rare disease company is seeking targeting molecules, advanced chemistries, or formulations to provide novel drug delivery systems targeting the joints.

Molecular Strategies for Targeted Drug Delivery to the Joints

Our client, a global leader in therapies for rare genetic diseases, is looking for novel approaches to target the primary cause of rare genetic skeletal muscle diseases, to transform the way patients feel, function, and survive. The following conditions are of interest: Muscular Dystrophies (Duchenne, Becker, FSHD, Limb-girdle, LAMA2, Emery-Dreifus, Ullrich, Oculopharyngeal) Myotonic Dystrophy Type 1 and 2, Pompe Disease, Nemaline Myopathy, X-linked Centronuclear Myopathy, RYR1-related myopathies and other rare genetic skeletal muscle diseases will be considered...

A  world-leading company in rare genetic diseases is looking for novel approaches to target the primary cause of rare genetic skeletal muscle diseases.

Seeking Novel Solutions to Treat Rare Genetic Skeletal Muscle Diseases

Haifa Group, a world leader in the field of fertilizers, is seeking novel, biodegradable, water-soluble chelating compounds for micronutrients. The team behind this campaign is interested in chelating compounds that can replace commercially available chelates (e.g., EDTA, EDDHA) while maintaining comparable elemental load and performance in fertigation applications. <h3>Approaches of Interest: </h3> <ul> <li>The micronutrients that are of interest are: Iron, Copper, Zinc and Manganese.</li> <li>Chelating compounds must be comparable to the commercially available chelates, including...</li></ul>

Haifa Group is seeking biodegradable, water-soluble chelating compounds for micronutrients that must be comparable to commercially available chelates.

Seeking Novel Chelated Fertilizers 

Novo Nordisk established the Transformational Prevention Unit (TPU) to develop scientifically valid and commercially scalable solutions to predict and pre-empt the risk of obesity and its consequences, so people can live healthier and longer lives. The TPU is committed to building novel, multi-sector partnerships that combine scientific, technological and implementation expertise across four inter-related product categories to deliver impactful solutions. To achieve this, the TPU team at Novo Nordisk is seeking science data-backed opportunities to advance...

Novo Nordisk is seeking scientifically validated biological solutions for weight management and the promotion of metabolic health.

Novel Biological and Pharmacological Interventions for Obesity Prevention

A global health company is seeking novel therapeutics for chronic and situational anxiety. Specifically, our client is interested in novel treatments with rapid onset that can be administered either daily (with a target of 4-6 hours of efficacy) for situational anxiety, or as a long-acting treatment (preferably monthly treatment) for chronic anxiety. Therapeutics should have minimal side effects such as gastrointestinal issues, sedation, ataxia, and lethargy. Safety and efficacy studies in rodents, dogs and cats are preferred. Approaches of Interest: <ul> ...</ul>

A leading health company is seeking novel therapeutics for chronic and situational anxiety which have in vivo validation, with a preference for oral, topical or subcutaneous delivery.

Seeking Novel Therapeutics for Anxiety Management

A world-leading health company is seeking novel therapeutics for obesity, with safety and efficacy data, preferably in canine models. Approaches should help manage obesity and reduce body condition score, with greater efficacy than diet and/or exercise alone. Our client aims to bring a novel treatment to market within 3-5 years. Approaches should allow for oral or injectable delivery, ideally with daily (oral) or monthly (injectable) dosing. Our client is seeking therapeutics with strong safety profile, with minimal side-effects (i.e. no gastrointestinal...

A world-leading health company is seeking novel oral or injectable therapeutics to address obesity, preferably with canine safety and efficacy data.

Seeking Novel Oral or Injectable Therapeutics to Treat Obesity

A nephrology-focused pharmaceutical company is seeking innovative drug discovery concepts and druggable targets specifically for genetic kidney diseases, with a focus on rare conditions. They are also interested in novel drug discovery platforms that can be utilized for genetic kidney disease research. Approaches of Interest: <ul> <li>Therapeutic targets for Alport Syndrome; submissions should focus on either (i) small molecules, peptides, and druggable targets that can modulate COL4A3, COL4A4, and COL4A5 gene function or (ii) therapeutics targets that are critical...</li></ul>

A nephrology-focused pharmaceutical company is seeking novel drug discovery concepts for the correction of impaired function of causative genes of rare genetic kidney diseases, as well as druggable targets in Alport Syndrome.

Novel Drug Discovery Concepts and Targets within Genetic Kidney Diseases

An immunology&#x2011;focused pharmaceutical company is seeking novel druggable targets and/or molecules that are involved in regulation of immunometabolism in inflammatory disease. Specifically, the team are looking to focus on targetable molecules with demonstrated involvement in human pathology (e.g. a role in pathways linked to disease). Approaches of Interest: <ul> <li>Approaches that dramatically alter the immune cell state (e.g. macrophage M1 to M2 transition, or Th1 to Treg transition)</li> <li>Targets that specifically express in immune cells</li> <li>Improved modulation of pathways...</li></ul>

An immunology-focused pharmaceutical company is seeking druggable targets and/or molecules involved in metabolic regulation of immune function, with a specific focus on targetable molecules with demonstrated involvement in human pathology.

Engage with world leading R&D teams

Active campaigns

ico